Q-omics provides the consensus-scored ZNF599 profile across patient tissues and cancer cell-line models. ZNF599 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZNF599 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, ZNF599 RNA expression shows 20,993 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, KICH, and ACC as cancer lineages where ZNF599 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF599 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF599 survival associations across molecular data types. ZNF599 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF599 RNA expression–survival associations across cancer types. High ZNF599 expression shows unfavorable associations in ACC and LGG, but favorable associations in HNSC, UCS, BRCA and UVM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ZNF599 RNA expression.
This table summarizes ZNF599 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF599. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF599 shows lower tumor expression in KICH, THCA and UCEC and higher tumor expression in LIHC, BLCA and CHOL. The KICH box plot shows higher ZNF599 RNA expression in normal versus tumor tissue (log2 FC = −1.242, t-test p < 0.001).
This table shows molecular features associated with ZNF599 in patient tissues and cancer cell lines. In patient samples, ZNF599 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF599 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
